Trajectories of mean arterial pressure/norepinephrine equivalent dose index in patients with septic shock receiving low-dose hydrocortisone: a retrospective cohort study in Thailand

Auttawut Chalermwutanon; Sawangjit Saejaow; Veerapong Vattanavanit

doi:10.4266/acc.000125

Articles

Page Path: HOME > Acute Crit Care > Volume 41(1); 2026 > Article

Original Article Infection Trajectories of mean arterial pressure/norepinephrine equivalent dose index in patients with septic shock receiving low-dose hydrocortisone: a retrospective cohort study in Thailand: Acute and Critical Care 2026;41(1):107-116.
DOI: https://doi.org/10.4266/acc.000125
Published online: February 9, 2026

Auttawut Chalermwutanon¹

, Sawangjit Saejaow²

, Veerapong Vattanavanit³

¹Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand

²Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand

³Critical Care Medicine Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand

Corresponding author: Veerapong Vattanavanit Critical Care Medicine Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand Tel: +66-7445-1452 Fax: +66-7428-1457 Email: vveerapong@gmail.com

• Received: December 23, 2024 • Revised: November 1, 2025 • Accepted: November 5, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,238 Views
58 Download

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
KEY MESSAGES
NOTES
SUPPLEMENTARY MATERIALS
REFERENCES

Abstract

Background
We aimed to analyze the trajectories of the mean arterial pressure/norepinephrine equivalent dose (MAP/NEQ) index in patients with septic shock treated with low-dose hydrocortisone and to determine the association of these trajectories with mortality.
Methods
A retrospective cohort of 203 patients with septic shock receiving low-dose hydrocortisone was examined. MAP and NEQ data were collected from electronic health records, and group-based trajectory modeling was employed to identify distinct patterns in the MAP/NEQ index over the initial 72 hours of treatment. Univariable and multivariable logistic regression analyses were conducted to assess the associations of MAP/NEQ index trajectories with clinical variables and in-hospital mortality.
Results
The overall in-hospital mortality rate was 56.2%. Three MAP/NEQ index trajectory patterns were identified: unchanged (76.8%), gradually increased (14.3%), and rapidly increased (8.9%). The shock reversal rates were 50% for the unchanged group, 89.7% for the gradually increased group, and 100% for the rapidly increased group. Compared with the unchanged group, both gradually and rapidly increased groups were associated with significantly lower mortality, with adjusted odds ratios of 0.15 (95% CI, 0.05–0.40; P<0.001) and 0.29 (95% CI, 0.09–0.92; P=0.035), respectively.
Conclusions
In patients with septic shock treated with low-dose hydrocortisone, gradually and rapidly increased MAP/NEQ index trajectories were associated with significantly lower mortality risks and higher rates of shock reversal compared to those with unchanged trajectories. These findings highlight the importance of monitoring the MAP/NEQ index to guide treatment and improve septic shock outcomes.
Key Words: hydrocortisone; mean arterial pressure; mortality; septic shock; vasoconstrictor agents

INTRODUCTION

Septic shock, a medical emergency characterized by severe infection, leads to reduced blood flow and oxygen delivery to tissues. This condition is frequently encountered in intensive care units (ICUs) and is recognized by the World Health Organization as a significant global public health issue. Approximately 85% of sepsis cases and sepsis-related deaths occur in low-to-middle-income countries [1]. A systematic review reported a sepsis-related hospital mortality rate of 27% globally [2]. In Thailand, the prevalence of shock among patients with sepsis is 30.5%, with a 28-day mortality rate of 38% [3].

The use of corticosteroids in septic shock has been debated and researched for more than four decades. The benefits of corticosteroids remain controversial owing to varying patient selection criteria, types and doses of corticosteroids, and differences in administration duration, leading to inconsistent primary outcomes regarding mortality. However, secondary outcomes have consistently shown that corticosteroids reduce the duration of vasopressor use [4,5]. Current treatment guidelines for septic shock, based on the 2021 guidelines of the Surviving Sepsis Campaign, recommend the use of intravenous corticosteroids in patients who require escalating doses of vasopressors [6].

Recently, the ratio of mean arterial pressure (MAP) to norepinephrine equivalent dose (NEQ), known as the MAP/NEQ index, has been introduced as a novel marker for assessing septic shock severity. The MAP/NEQ demonstrated improved prognostic validity compared with commonly used sepsis severity scores and vasopressor dose alone [7]. The MAP/NEQ has been used to predict early mortality in patients with shock treated with vasopressors [8] and to determine the appropriate timing for initiating enteral nutrition in patients with shock [9].

As corticosteroids reduce the duration of vasopressor use, this can be expected to influence the trajectory of the MAP/NEQ index over time after the initiation of hydrocortisone administration. In this study, we aimed to characterize hemodynamic response trajectories in patients with septic shock receiving low-dose hydrocortisone in real-world clinical practice rather than to test treatment efficacy in a trial setting. We hypothesized that tracking the MAP/NEQ index trajectories after starting low-dose intravenous hydrocortisone treatment would predict septic shock recovery and in-hospital mortality.

MATERIALS AND METHODS

The study was approved by the Human Ethics Committee of the Faculty of Medicine at Prince of Songkla University (No. 66-281-14-4). All methods were performed in accordance with the relevant guidelines and regulations, and the study adhered to the Declaration of Helsinki. The requirement for informed consent was waived because of the retrospective study design.

Study Design

This was a single-center, retrospective cohort study of patients with septic shock admitted to the medical intensive care unit (MICU) of Songklanagarind Hospital from January 1, 2017, to December 31, 2022. The hospital is an 850-bed academic tertiary care facility with 12 MICU beds. Sepsis management at our hospital followed a sepsis protocol adapted from the 2016 Surviving Sepsis Campaign guidelines [10]. Vasoactive agents available at our hospital include norepinephrine, epinephrine, dopamine, and dobutamine. The criteria for initiating low-dose hydrocortisone treatment in patients with septic shock receiving high-dose vasopressors were left to the physician's discretion.

This study included adult patients aged ≥18 years diagnosed with septic shock according to the Sepsis-3 definition [11] and treated with hydrocortisone at a dose of 50 mg every 6 hours. Another inclusion criterion was the availability of the vital signs and vasopressor use data at 0 hours and at two or more of five time points at 6, 12, 24, 48, and 72 hours after receiving hydrocortisone, with an allowance of ±1 hour. Patients with preexisting adrenal insufficiency and those who received steroids before developing septic shock were excluded. Patients who received hydrocortisone treatment exceeding 200 mg/day for septic shock or for other indications were also excluded. Additionally, pregnant patients were excluded from the study.

Data Collection

Patient data collected from electronic medical records were sex, age, height, weight, underlying diseases, date of hospital admission, initial lactate level, and severity scores, including Sequential Organ Failure Assessment (SOFA) and non-cardiovascular SOFA scores. Treatment information, including the administration of antibiotics, vasopressors, inotropes (dosage and duration), and hydrocortisone (dosage and time of initiation), was also obtained. Vital signs were recorded at the time of shock diagnosis and at 0, 6, 12, 24, 48, and 72 hours after receiving hydrocortisone. Hyperglycemia or hypernatremia was also noted, and information on the number of days spent in the hospital and the discharge status was collected.

NEQ was defined as follows: norepinephrine dose (µg/kg/min) + epinephrine dose (µg/kg/min) + 1/10 × phenylephrine dose (µg/kg/min) + 1/100 × dopamine dose (µg/kg/min) + 1/8 × metaraminol dose (µg/kg/min) + 2.5 × vasopressin dose (U/min) + 10 × angiotensin II dose (µg/kg/min) [12].

Shock reversal was defined as recovery to MAP ≥65 mm Hg with no vasopressor administration for at least 24 hours [13]. Hyperglycemia was defined as blood sugar ≥150 mg/dl on two consecutive occasions within 72 hours of starting hydrocortisone administration [13]. Hypernatremia was defined as a blood sodium level ≥150 mEq/L at any time within 72 hours of starting hydrocortisone administration [14].

Outcome Assessment

The primary outcome was the in-hospital mortality rate. Secondary outcomes included the shock reversal rate, time from septic shock to shock reversal, hyperglycemia or hypernatremia, and length of hospital stay.

Statistical Analyses

Group-based trajectory models (GBTMs) are useful for identifying clusters of individuals with distinct developmental trajectories within a cohort. In this study, individuals within the same cluster followed similar progressions in the MAP/NEQ index measured repeatedly at six time points. For the GBTMs, we used the censored normal model because the MAP/NEQ index is a continuous variable. Initially, we assumed the trajectory patterns to be cubic, with the MAP/NEQ index as the dependent variable and time (hour) as the independent variable.

Model selection involved determining both the optimal number of groups and the shape of each trajectory. Several models with varying group numbers and trajectory forms were compared to identify the best fit. The model fit was evaluated using several statistical criteria, including the Bayesian Information Criterion (BIC), the log Bayes factor (2 log_eB₁₀), and the average posterior probability for group membership. A smaller BIC and a value of 2 log_eB₁₀ >10 were considered indicators of superior model fit. Each trajectory group was required to have an average posterior probability >0.7 and a minimum group membership of 5% to ensure adequate classification and model stability [15,16].

For descriptive analyses, continuous variables are presented as the median with interquartile range, whereas categorical variables are expressed as percentage. Baseline variables were compared between groups using the Kruskal-Wallis test or the Mann-Whitney U-test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. When the overall trend was significant, post hoc pairwise comparisons were conducted using the Bonferroni correction.

Patients were classified into three MAP/NEQ index trajectory groups based on individual linear slope parameters as unchanged, gradually increased, and rapidly increased. The relationship between the MAP/NEQ index trajectory group and the primary outcome was examined using multivariable logistic regression models. The covariates included in the model for adjustment were age, nosocomial infection, intravenous fluid resuscitation, appropriate antibiotics, non-cardiovascular SOFA score, and initial lactate level. Odds ratios (ORs) and 95% CIs were estimated using logistic regression. The software used for GBTM was Stata version 16 (StataCorp.), with an added user-written Stata command called "Traj," developed by Jones and Nagin for trajectory modeling [17].

RESULTS

In this study, 265 patients with septic shock admitted to the MICU were eligible for inclusion. After excluding 62 patients (4 with adrenal insufficiency, 32 with preexisting steroid treatment, 4 receiving a different steroid dose, and 22 with incomplete data), 203 patients were included in the study cohort. A flowchart of the patient selection process is shown in Figure 1. The baseline characteristics according to primary outcome are presented in Supplementary Table 1. Type of infection, positive hemoculture, amount of intravenous fluid, appropriate antibiotic use, and severity score significantly affected mortality.

Model comparison using the BIC, the log Bayes factor, and minimum group membership favored the model with three trajectories as having the optimal fit. By contrast, the models with two- or four-groups yielded poorer BIC values and included implausibly small subgroups (Supplementary Table 2). The assessment of model adequacy for the three-trajectory model is presented in Supplementary Table 3. The average posterior probabilities for all trajectory groups exceeded the recommended cutoff of 0.7, indicating acceptable classification quality.

Figure 2 illustrates the MAP/NEQ trajectories measured at 0, 6, 12, 24, 48, and 72 hours after hydrocortisone administration. The study population was categorized into three distinct patterns of unchanged (n=156, 76.8%), gradually increased (n=29, 14.3%), and rapidly increased (n=18, 8.9%). Distinct trajectories emerged within the first 6 hours and were clearly separated by 24 hours. Patients whose MAP/NEQ index increased above 500 mm Hg/µg/kg/min during this early period generally followed favorable (gradually or rapidly increasing) trajectories, whereas those remaining below 300 mm Hg/µg/kg/min typically belonged to the unchanged, non-responder group.

The baseline characteristics of the MAP/NEQ trajectory groups are presented in Table 1. The median patient age was 69 years, and 53.2% of the patients were male. Significant differences among the three groups were observed in terms of catheter-associated urinary tract infection, baseline SOFA score, non-cardiovascular SOFA score, initial lactate level, MAP/NEQ index at the time of starting hydrocortisone treatment, shock reversal rate, time to shock reversal, occurrence of hypernatremia, and in-hospital mortality.

The hemodynamic variables and vasoactive agents used at the time of shock diagnosis and initiation of hydrocortisone treatment are detailed in Table 2. The initial median MAP/NEQ index was 1,103.1 mm Hg/µg/kg/min, with no significant differences among the three groups. However, after initiating hydrocortisone treatment, the median MAP/NEQ indices for the unchanged and gradually increased groups were 245.4 mm Hg/µg/kg/min and 432.2 mm Hg/µg/kg/min, respectively, which were significantly lower than the median MAP/NEQ index of 1,318.5 mm Hg/µg/kg/min for the rapidly increased group.

Table 3 shows the associations between MAP/NEQ index trajectory groups and mortality. Compared with the unchanged group, the gradually increased and rapidly increased groups were significantly associated with a lower risk of mortality after adjusting for confounders (OR, 0.15; 95% CI, 0.05–0.40; P<0.001 and OR, 0.29; 95% CI, 0.09-0.92; P=0.035, respectively).

DISCUSSION

This study focused on analyzing MAP/NEQ index trajectories in patients with septic shock receiving low-dose hydrocortisone as part of clinical care. Hydrocortisone was considered adjunctive therapy rather than an intervention under investigation. We identified three MAP/NEQ index trajectories after initiating hydrocortisone treatment. The groups with an increased MAP/NEQ index, whether gradual or rapid, were significantly associated with a lower risk of in-hospital mortality and higher rates of shock reversal than the unchanged group.

To the best of our knowledge, this is the first study to evaluate the trajectories of hemodynamic responses to low-dose bolus hydrocortisone using the MAP/NEQ index. Previous studies have examined hemodynamic responses to various hydrocortisone preparations. For instance, Bargate et al. found that, in patients with septic shock, a bolus of hydrocortisone with fludrocortisone increased the systolic blood pressure, diastolic blood pressure, and MAP within 2–4 hours of steroid initiation [18]. Similarly, Keh et al. [19] observed an increase in MAP on day 1 and a decrease in norepinephrine requirements with continuous hydrocortisone administration. Our study used the MAP/NEQ index, which represents the ratio of blood pressure to vasopressor dose and is analogous to the PaO₂/FiO₂ ratio used in respiratory physiology [7]. Our results showed that the MAP/NEQ index trajectories were notably different 24 hours after starting hydrocortisone treatment. The increase in MAP and decrease in NEQ can be attributed to the effects of hydrocortisone, which include direct effects on vascular tone, left ventricular afterload, immunologic effects, and levels of endothelial glucocorticoid receptors that reduce vasoplegia [20].

Our study reflects the real-life practice of using low-dose hydrocortisone for septic shock, with a median of 7 hours from septic shock onset to steroid administration. This aligns with guidelines recommending the initiation of steroids in patients treated with vasopressors for a minimum of 4 hours. The median NEQ dose was 0.25 µg/kg/min, which is consistent with the guideline-recommended dose for corticosteroids [6]. The median time from septic shock onset to shock reversal was 3 days, similar to that in the hydrocortisone group in the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock trial [21]. We used intermittent bolus doses of hydrocortisone for ease of administration, which have been associated with higher shock reversal rates on day 7 than continuous infusion [22].

We identified three patterns of MAP/NEQ index response to hydrocortisone. Unfortunately, most patients (76%) exhibited an unchanged pattern, potentially because the patients were steroid non-responders or were severely ill. This lack of response might reflect tissue resistance to glucocorticoids at the receptor level [23], genetic variability in glucocorticoid receptor sensitivity [24], or irreversible vasoplegia occurring in the late phase of septic shock. Previous studies have provided information on corticosteroid responders. For example, the corticosteroid therapy of septic shock study reported that 46.7% of patients with septic shock were steroid non-responders, which was defined as the absence of a response to a corticotropin test [14]. Similarly, a Thai study reported a non-responsiveness rate of 55.2% among patients with septic shock [25]. No benefit was found in using steroids in patients without a sufficient response in the adrenocorticotropic hormone (ACTH) stimulation test, defined as an increase ≤ 9 μg/dl in cortisol 30–60 minutes after ACTH administration. Therefore, steroid responsiveness might not be an appropriate index for hemodynamic response to hydrocortisone. Patients in our study appeared to be more severely affected than those in previous studies, as indicated by a mortality rate of 56.2% in patients with septic shock, compared to ≤50% in two recent major randomized trials of steroid use in septic shock [13,21].

An original study by Bosch et al. [7] reported the prognostic validity of the MAP/NEQ index using MIMIC-III and an electronic ICU database. The MAP/NEQ index within 24 hours of ICU admission ranged from 39 to 8,396 mm Hg/µg/kg/min in the MIMIC-III database. Tertiles were used to create MAP/NEQ cutoffs of < 136, 136–324, and ≥325 mm Hg/µg/kg/min, classified as severe, moderate, and mild severity, respectively. A previous study by Yang et al. [8] identified the MAP/NEQ index as an early mortality predictor in patients with shock using the MIMIC-IV database. Higher MAP/NEQ indices were associated with shorter hospital stays and lower mortality rates. A MAP/NEQ index ≤183 mm Hg/µg/kg/min was linked to a significantly increased mortality risk.

The MAP/NEQ index in our study was higher than those reported in previous studies by Bosch et al. [7] and Yang et al. [8] because we used a different NEQ formula. Previous studies used a formula developed in 2008 that included only norepinephrine, dopamine, epinephrine, and phenylephrine. The units for most vasoactive agents were µg/min, except for dopamine, which was measured in µg/kg/min with a conversion ratio of 1:2. Recently, Kotani et al. [12] updated the NEQ formula to include new vasopressors such as vasopressin and angiotensin II, suggesting its extension for use with the MAP/NEQ index. The updated formula uses units of µg/kg/min, with a conversion ratio of 1:100 for dopamine. This approach yields smaller denominator values and consequently higher MAP/NEQ ratios than those reported in earlier studies. Subsequent studies have shown that the updated NEQ formula demonstrated favorable predictive performance for mortality risk in patients with sepsis in ICUs [26] and supports its use in settings involving alternative vasoactive agents, such as angiotensin II [27] and methylene blue [28]. Our results suggest that using a single MAP/NEQ index as a prognostic marker in patients with septic shock receiving hydrocortisone can be more effective when measured at the time of starting hydrocortisone treatment than at the time of septic shock diagnosis.

The gradually and rapidly increased trajectory groups demonstrated better outcomes in terms of shock reversal, supporting the MAP/NEQ index as a reliable indicator of hemodynamic recovery in patients receiving hydrocortisone. In our study, MAP/NEQ trajectories were associated with both in-hospital mortality and shock reversal outcomes. Hydrocortisone use can lead to metabolic complications such as hyperglycemia and hypernatremia, both of which can worsen patient outcomes. In our study, hyperglycemia (≥150 mg/dl) occurred in approximately 60% of patients after initiation of hydrocortisone administration. Previous evidence suggests that a stable mean blood glucose level between 120 and 140 mg/dl is associated with lower ICU mortality and reduced hypoglycemia risk in patients with sepsis but without diabetes [29]. Hypernatremia (≥150 mEq/L) was observed mainly in the unchanged MAP/NEQ group and has been linked to poor prognosis in septic shock [30]. These findings suggest that, in patients who remain hemodynamically unchanged after 24–48 hours, the development of hypernatremia or persistent hyperglycemia should prompt reconsideration or discontinuation of hydrocortisone to avoid harm. Serial MAP/NEQ monitoring every 6–12 hours can help identify early steroid responders, whereas a persistently flat trajectory, characterized by MAP/NEQ values less than 300 mm Hg/µg/kg/min after 24–48 hours, should prompt reassessment of therapy. This trajectory-based approach could be incorporated into sepsis protocols to guide the timely escalation or de-escalation of corticosteroid treatment.

Our study has several limitations. First, its nature as a single-center study might introduce selection bias. Second, the limited sample size might have reduced the statistical power of the association analysis. Third, rapid hemodynamic fluctuations might have been missed because of the 6-hour data collection intervals. Fourth, data on potential confounders influencing mortality outcomes might not have been fully adjusted. Although fluid balance is an important confounder, only the total volume of fluid resuscitation was recorded because net balance was not preplanned in the study protocol. Moreover, other inflammatory markers, such as C-reactive protein and procalcitonin, were not routinely measured in our hospital. We acknowledge that the observed associations might reflect residual confounding or reverse causality; therefore, the trajectory–mortality relationship should be interpreted as prognostic rather than causal, given the retrospective design and lack of randomization. Fifth, only patients receiving bolus hydrocortisone were included; hence, the findings should not be directly extrapolated to continuous infusion regimens. Finally, the rapidly increased trajectory group, representing less than 10% of the cohort, might have reduced statistical stability and widened CIs, although model adequacy indices support the robustness of the trajectory classification.

In conclusion, three MAP/NEQ index trajectories in patients receiving hydrocortisone were identified using GBTMs. The rapidly and gradually increased trajectory patterns were associated with lower mortality and higher shock reversal than the unchanged trajectory pattern. The MAP/NEQ index trajectory patterns demonstrated the utility of MAP/NEQ index measurement in predicting outcomes in patients with septic shock receiving hydrocortisone. However, our results require further investigation with larger sample sizes and various populations.

KEY MESSAGES

▪ Three distinct mean arterial pressure/norepinephrine equivalent dose (MAP/NEQ) index trajectory patterns were identified in septic shock patients treated with low-dose hydrocortisone: unchanged, gradually increased, and rapidly increased.

▪ Gradually and rapidly increased MAP/NEQ trajectories were associated with significantly lower in-hospital mortality and higher shock reversal rates compared to unchanged trajectories.

NOTES

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

None.

ACKNOWLEDGMENTS

We appreciate the prompt responses of the Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkhla University; and the Medical Record Section, Songklanagarind Hospital.

AUTHOR CONTRIBUTIONS

Conceptualization: AC, SS, VV. Data curation: AC, VV. Formal analysis: AC, SS, VV. Methodology: AC, SS, VV. Project administration: VV. Visualization: VV. Writing original draft: VV. Writing - review & editing: AC, SS, VV. All authors read and agreed to the published version of the manuscript.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found via https://doi.org/10.4266/acc.000125.

Supplementary Table 1.

Characteristics of patients grouped by survival or death during the study period

acc-000125-Supplementary-Table-1.pdf

Supplementary Table 2.

Model fit statistics and group adequacy for trajectory models with 1–4 groups

acc-000125-Supplementary-Table-2.pdf

Supplementary Table 3.

Model adequacy results for the final three-trajectory model

acc-000125-Supplementary-Table-3.pdf

Figure 1.

Study flowchart showing patient screening and enrollment. ICU: intensive care unit.

Figure 2.

Trajectories of the MAP/NEQ index measured at 0, 6, 12, 24, 48, and 72 hours after hydrocortisone initiation. Three distinct patterns were identified: group 1 (blue), unchanged (non-responders, 76.8%); group 2 (red), gradually increased (delayed responders, 14.3%); and group 3 (green), rapidly increased (early responders, 8.9%). Divergence between trajectories became evident at 6 hours and was clearly pronounced by 24 hours. MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose.

Table 1.

Patient characteristics according to the MAP/NEQ index trajectories

Variable	All patients (n=203)	Unchanged group (n=156)	Gradually increased group (n=29)	Rapidly increased group (n=18)	P-value^c)
Age (yr)	69 (60–78)	69 (59–78)	74 (57–80)	74 (66–78)	0.482
Male sex	108 (53.2)	85 (54.5)	14 (48.3)	9 (50.0)	0.794
Comorbidity
Hypertension	73 (35.9)	54 (34.6)	15 (51.7)	4 (22.2)	0.094
Diabetes mellitus	66 (32.5)	51 (32.7)	13 (44.8)	2 (11.1)	0.056
Malignancy	70 (34.5)	55 (35.3)	8 (27.6)	7 (38.9)	0.668
CKD	42 (20.7)	32 (20.5)	6 (20.7)	4 (22.2)	0.986
CAD	46 (22.7)	40 (25.6)	5 (17.2)	1 (5.6)	0.118
Stroke	32 (15.8)	20 (12.9)	6 (20.7)	6 (33.3)	0.059
Cirrhosis	15 (7.4)	11 (7.0)	3 (10.3)	1 (5.6)	0.785
Chronic lung disease	23 (11.3)	19 (12.2)	0	4 (22.2)	0.051
Primary site of infection
Community-acquired infection	107 (52.7)	81 (51.9)	17 (58.6)	9 (50.0)	0.779
Pneumonia	42 (20.7)	30 (19.2)	7 (24.1)	5 (27.8)	0.618
UTI	18 (8.9)	13 (8.3)	4 (13.8)	1 (5.6)	0.557
IAI	18 (8.9)	15 (9.6)	2 (6.9)	1 (5.6)	0.782
Nosocomial infection	96 (47.3)	75 (48.1)	12 (41.4)	9 (50.0)	0.779
HAP	37 (18.2)	29 (18.6)	5 (17.2)	3 (16.7)	0.969
VAP	21 (10.3)	16 (10.3)	4 (13.8)	1 (5.6)	0.664
CA-UTI	12 (5.9)	6 (3.8)	1 (3.4)	5 (27.8)^a	0.003
CR-BSI	6 (2.9)	5 (3.2)	1 (3.4)	0	0.738
Skin/soft tissue	8 (3.9)	7 (4.5)	1 (3.4)	0	0.644
Hemoculture positive	69 (33.9)	56 (35.9)	10 (34.5)	3 (16.7)	0.264
Baseline SOFA score	10 (8–11)	10 (8–11)	10 (8–11)	9 (7–9)^a	0.039
Baseline non-cardiovascular SOFA score	7 (5–8)	7 (5–8)	7 (5–8)	6 (4–6)^a	0.024
Initial lactate (mmol/L)	3.0 (2.0–5.1)	3.2 (2.0–5.6)	3.4 (2.3–4.8)	2.2 (2.0–2.8)^a)	0.015
Time from septic shock to the first dose of hydrocortisone (hr)	7 (2–23)	8 (3–23)	9 (2–21)	3 (1–12)	0.437
Hydrocortisone total doses	14 (8–24)	14 (8–24)	19 (11–24)	15 (7–21)	0.538
Intravenous fluid resuscitation (ml)	1,300 (1,000–2,000)	1,100 (800–2,000)	1,300 (1,000–1,800)	1,850 (1,000–2,000)	0.089
Appropriate antibiotics	190 (93.6)	147 (94.2)	27 (93.1)	16 (88.9)	0.676
Outcome
Shock reversal rate	122 (60.1)	78 (50.0)	26 (89.7)^a	18 (100)^a)	<0.001
Time from septic shock to shock reversal (day)	3 (2–5)	3 (2–4)	4 (2–5)	1 (1–3)^b)	0.005
Hyperglycemia	123 (60.6)	93 (59.6)	19 (65.5)	11 (61.1)	0.836
Hypernatremia	27 (13.3)	26 (16.7)	1 (3.4)	0	0.034
Length of hospital stay (day)	13 (5–28)	13 (5–26)	19 (11–41)	13 (9–26)	0.069
In-hospital mortality	114 (56.2)	101 (64.7)	7 (24.1)	6 (33.3)^a),b)	<0.001

Values are presented as median (interquartile range) or number (%).

MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose; CKD: chronic kidney disease; CAD: coronary artery disease; UTI: urinary tract infection; IAI: intra-abdominal infection; HAP: hospital-acquired pneumonia; VAP: ventilator-associated pneumonia; CA-UTI: catheter-associated urinary tract infection; CR-BSI: catheter-related bloodstream infection; SOFA: Sequential Organ Failure Assessment.

^a), b)Indicates significant pairwise differences after correction as follows:

^a)A significant difference compared with the unchanged group;

^b)Indicates a significant difference compared with the gradually increased group;

^c)P-values are derived from the overall comparison across the four trajectory groups, with statistical significance defined as P<0.05. Post hoc pairwise comparisons were performed using the Bonferroni correction.

Table 2.

Hemodynamic variables at the time of shock diagnosis and of starting hydrocortisone according to the MAP/NEQ index trajectories

Variable	All patients (n=203)	Unchanged group (n=156)	Gradually increased group (n=29)	Rapidly increased group (n=18)	P-value^c)
At the time of septic shock diagnosis
HR (beats/min)	110 (92–131)	111 (90–131)	125 (92–140)	102 (93–113)	0.133
MAP (mm Hg)	63 (57–68)	63 (57–66)	65 (61–72)	62 (58–66)	0.096
NEQ (µg/kg/min)	0.05 (0.04–0.09)	0.06 (0.04–0.10)	0.06 (0.04–0.12)	0.05 (0.04–0.08)	0.202
MAP/NEQ index (mm Hg/µg/kg/min)	1,103.1 (605.1–1,458.3)	1,069.2 (605.1–1,395.4)	1,092 (564.7–1,469.2)	1,323.3 (653.3–1,842.1)	0.233
At the time of starting hydrocortisone treatment
HR (beats/min)	110 (90–128)	113 (92–131)	108 (84–123)	99 (84–107)	0.090
MAP (mm Hg)	72 (66–81)	71 (64–80)	75 (70–82)	76 (68–82)	0.050
NEQ (µg/kg/min)	0.25 (0.12–0.49)	0.30 (0.15–0.51)	0.17 (0.15–0.42)	0.06 (0.05–0.11)^a)	< 0.001
MAP/NEQ index (mm Hg/µg/kg/min)	276.8 (150.9–562.2)	245.4 (131.3–481.9)	432.2 (214.3–517.3)	1318.5 (809.1–1925.5)^a),b)	< 0.001

Values are presented as median (interquartile range).

MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose; HR: heart rate.

^a), b)Indicates significant pairwise differences after correction as follows:

^a)A significant difference compared with the unchanged group;

^b)A significant difference compared with the gradually increased group;

Table 3.

ORs of in-hospital mortality according to the MAP/NEQ index trajectories

Group	In-hospital mortality, No. (%)	OR (95% CI)		Adjusted P-value
Group	In-hospital mortality, No. (%)	Unadjusted	Adjusted^a)	Adjusted P-value
Unchanged	101 (64.7)	Reference	Reference	Reference
Gradually increased	7 (24.1)	0.17 (0.07–0.43)	0.15 (0.05–0.40)	<0.001
Rapidly increased	6 (33.3)	0.27 (0.10–0.76)	0.29 (0.09–0.92)	0.035

MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose; OR: odds ratio.

^a)Adjusted for age, nosocomial infection, intravenous fluid resuscitation, appropriate antibiotics, noncardiovascular Sequential Organ Failure Assessment score, and initial lactate level.

REFERENCES

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020;395:200-11.Article PubMed PMC
2. Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med 2020;46:1552-62.Article PubMed PMC PDF
3. Tancharoen L, Pairattanakorn P, Thamlikitkul V, Angkasekwinai N. Epidemiology and burden of sepsis at Thailand's largest university-based national tertiary referral center during 2019. Antibiotics (Basel) 2022;11:899.Article
4. Gibbison B, López-López JA, Higgins JP, Miller T, Angelini GD, Lightman SL, et al. Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care 2017;21:78.Article PubMed PMC PDF
5. Pirracchio R, Annane D, Waschka AK, Lamontagne F, Arabi YM, Bollaert PE, et al. Patient-level meta-analysis of low-dose hydrocortisone in adults with septic shock. NEJM Evid 2023;2:EVIDoa2300034.Article PubMed
6. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49:e1063-143.Article PubMed
7. Bosch NA, Teja B, Wunsch H, Walkey AJ. Characterization and validation of a novel measure of septic shock severity. Intensive Care Med 2020;46:135-7.Article PubMed PDF
8. Yang J, Zou X, Wang R, Kang Y, Ou X, Wang B, et al. Mean arterial pressure/norepinephrine equivalent dose index as an early measure for mortality risk in patients with shock on vasopressors. Shock 2024;61:253-9.Article PubMed
9. Wang L, Yang H, Cheng Y, Fu X, Yao H, Jin X, et al. Mean arterial pressure/norepinephrine equivalent dose index as an early measure of initiation time for enteral nutrition in patients with shock: a prospective observational study. Nutrition 2022;96:111586.Article PubMed
10. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017;45:486-552.Article PubMed
11. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801-10.Article PubMed PMC
12. Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity. Crit Care 2023;27:29.Article PubMed PMC PDF
13. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378:809-18.Article PubMed
14. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.Article PubMed
15. Nguena Nguefack HL, Pagé MG, Katz J, Choinière M, Vanasse A, Dorais M, et al. Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches. Clin Epidemiol 2020;12:1205-22.Article PubMed PMC
16. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Res 2001;29:374-93.Article PDF
17. Jones BL, Nagin DS. A note on a Stata plugin for estimating group-based trajectory models. Sociol Res 2013;42:608-13.Article PDF
18. Bagate F, Coppens A, Masi P, de Prost N, Carteaux G, Razazi K, et al. Cardiac and vascular effects of low-dose steroids during the early phase of septic shock: an echocardiographic study. Front Cardiovasc Med 2022;9:948231.Article PubMed PMC
19. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-20.Article PubMed
20. Goodwin JE, Feng Y, Velazquez H, Sessa WC. Endothelial glucocorticoid receptor is required for protection against sepsis. Proc Natl Acad Sci U S A 2013;110:306-11.Article PubMed PMC
21. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018;378:797-808.Article PubMed
22. Tilouche N, Jaoued O, Ali HB, Gharbi R, Fekih Hassen M, Elatrous S, et al. Comparison between continuous and intermittent administration of hydrocortisone during septic shock: a randomized controlled clinical trial. Shock 2019;52:481-6.Article PubMed
23. Fredrick FC, Meda AK, Singh B, Jain R. Critical illness-related corticosteroid insufficiency: latest pathophysiology and management guidelines. Acute Crit Care 2024;39:331-40.Article PubMed PMC PDF
24. Duan ZX, Gu W, Du DY, Hu P, Jiang DP, Zhu PF, et al. Distributions of glucocorticoid receptor gene polymorphisms in a Chinese Han population and associations with outcome after major trauma. Injury 2009;40:479-83.Article PubMed
25. Ratanarat R, Promsin P, Srivijitkamol A, Leemingsawat C, Permpikul C. Diagnosis of corticosteroid insufficiency in Thai patients with septic shock. J Med Assoc Thai 2010;93 Suppl 1:S187-95.PubMed
26. Li W, Wang Y, Abuduaini B, Li X, Pan P, Cui J, et al. Prognostic evaluation of the norepinephrine equivalent score and the vasoactive-inotropic score in patients with sepsis and septic shock: a retrospective cohort study. Front Cardiovasc Med 2024;11:1415769.Article PubMed PMC
27. Busse LW, Ten Lohuis C, Xu H, Jannuzzo C, Lyles RH, Teixeira JP, et al. Angiotensin II, conventional vasopressor therapy, and mortality in shock: a large, multicenter, propensity score-weighted analysis. Ann Intensive Care 2025;15:104.Article PubMed PMC
28. Xue S, Li L, Liu Z, Lyu F, Wu F, Shi P, et al. Predicting responsiveness to fixed-dose methylene blue in adult patients with septic shock using interpretable machine learning: a retrospective study. Sci Rep 2025;15:7254.Article PubMed PMC PDF
29. Lu Z, Tao G, Sun X, Zhang Y, Jiang M, Liu Y, et al. Association of blood glucose level and glycemic variability with mortality in sepsis patients during ICU hospitalization. Front Public Health 2022;10:857368.Article PubMed PMC
30. Shi MQ, Chen J, Ji FH, Zhou H, Peng K, Wang J, et al. Prognostic impact of hypernatremia for septic shock patients in the intensive care unit. World J Clin Cases 2025;13:95430.Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Trajectories of mean arterial pressure/norepinephrine equivalent dose index in patients with septic shock receiving low-dose hydrocortisone: a retrospective cohort study in Thailand

Acute Crit Care. 2026;41(1):107-116. Published online February 9, 2026

DOI: https://doi.org/10.4266/acc.000125

XML Download

Figure

Trajectories of mean arterial pressure/norepinephrine equivalent dose index in patients with septic shock receiving low-dose hydrocortisone: a retrospective cohort study in Thailand

Figure 1. Study flowchart showing patient screening and enrollment. ICU: intensive care unit.

Figure 2. Trajectories of the MAP/NEQ index measured at 0, 6, 12, 24, 48, and 72 hours after hydrocortisone initiation. Three distinct patterns were identified: group 1 (blue), unchanged (non-responders, 76.8%); group 2 (red), gradually increased (delayed responders, 14.3%); and group 3 (green), rapidly increased (early responders, 8.9%). Divergence between trajectories became evident at 6 hours and was clearly pronounced by 24 hours. MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose.

Figure 1.

Figure 2.

Trajectories of mean arterial pressure/norepinephrine equivalent dose index in patients with septic shock receiving low-dose hydrocortisone: a retrospective cohort study in Thailand

Variable	All patients (n=203)	Unchanged group (n=156)	Gradually increased group (n=29)	Rapidly increased group (n=18)	P-value^c)
Age (yr)	69 (60–78)	69 (59–78)	74 (57–80)	74 (66–78)	0.482
Male sex	108 (53.2)	85 (54.5)	14 (48.3)	9 (50.0)	0.794
Comorbidity
Hypertension	73 (35.9)	54 (34.6)	15 (51.7)	4 (22.2)	0.094
Diabetes mellitus	66 (32.5)	51 (32.7)	13 (44.8)	2 (11.1)	0.056
Malignancy	70 (34.5)	55 (35.3)	8 (27.6)	7 (38.9)	0.668
CKD	42 (20.7)	32 (20.5)	6 (20.7)	4 (22.2)	0.986
CAD	46 (22.7)	40 (25.6)	5 (17.2)	1 (5.6)	0.118
Stroke	32 (15.8)	20 (12.9)	6 (20.7)	6 (33.3)	0.059
Cirrhosis	15 (7.4)	11 (7.0)	3 (10.3)	1 (5.6)	0.785
Chronic lung disease	23 (11.3)	19 (12.2)	0	4 (22.2)	0.051
Primary site of infection
Community-acquired infection	107 (52.7)	81 (51.9)	17 (58.6)	9 (50.0)	0.779
Pneumonia	42 (20.7)	30 (19.2)	7 (24.1)	5 (27.8)	0.618
UTI	18 (8.9)	13 (8.3)	4 (13.8)	1 (5.6)	0.557
IAI	18 (8.9)	15 (9.6)	2 (6.9)	1 (5.6)	0.782
Nosocomial infection	96 (47.3)	75 (48.1)	12 (41.4)	9 (50.0)	0.779
HAP	37 (18.2)	29 (18.6)	5 (17.2)	3 (16.7)	0.969
VAP	21 (10.3)	16 (10.3)	4 (13.8)	1 (5.6)	0.664
CA-UTI	12 (5.9)	6 (3.8)	1 (3.4)	5 (27.8)^a	0.003
CR-BSI	6 (2.9)	5 (3.2)	1 (3.4)	0	0.738
Skin/soft tissue	8 (3.9)	7 (4.5)	1 (3.4)	0	0.644
Hemoculture positive	69 (33.9)	56 (35.9)	10 (34.5)	3 (16.7)	0.264
Baseline SOFA score	10 (8–11)	10 (8–11)	10 (8–11)	9 (7–9)^a	0.039
Baseline non-cardiovascular SOFA score	7 (5–8)	7 (5–8)	7 (5–8)	6 (4–6)^a	0.024
Initial lactate (mmol/L)	3.0 (2.0–5.1)	3.2 (2.0–5.6)	3.4 (2.3–4.8)	2.2 (2.0–2.8)^a)	0.015
Time from septic shock to the first dose of hydrocortisone (hr)	7 (2–23)	8 (3–23)	9 (2–21)	3 (1–12)	0.437
Hydrocortisone total doses	14 (8–24)	14 (8–24)	19 (11–24)	15 (7–21)	0.538
Intravenous fluid resuscitation (ml)	1,300 (1,000–2,000)	1,100 (800–2,000)	1,300 (1,000–1,800)	1,850 (1,000–2,000)	0.089
Appropriate antibiotics	190 (93.6)	147 (94.2)	27 (93.1)	16 (88.9)	0.676
Outcome
Shock reversal rate	122 (60.1)	78 (50.0)	26 (89.7)^a	18 (100)^a)	<0.001
Time from septic shock to shock reversal (day)	3 (2–5)	3 (2–4)	4 (2–5)	1 (1–3)^b)	0.005
Hyperglycemia	123 (60.6)	93 (59.6)	19 (65.5)	11 (61.1)	0.836
Hypernatremia	27 (13.3)	26 (16.7)	1 (3.4)	0	0.034
Length of hospital stay (day)	13 (5–28)	13 (5–26)	19 (11–41)	13 (9–26)	0.069
In-hospital mortality	114 (56.2)	101 (64.7)	7 (24.1)	6 (33.3)^a),b)	<0.001

Variable	All patients (n=203)	Unchanged group (n=156)	Gradually increased group (n=29)	Rapidly increased group (n=18)	P-value^c)
At the time of septic shock diagnosis
HR (beats/min)	110 (92–131)	111 (90–131)	125 (92–140)	102 (93–113)	0.133
MAP (mm Hg)	63 (57–68)	63 (57–66)	65 (61–72)	62 (58–66)	0.096
NEQ (µg/kg/min)	0.05 (0.04–0.09)	0.06 (0.04–0.10)	0.06 (0.04–0.12)	0.05 (0.04–0.08)	0.202
MAP/NEQ index (mm Hg/µg/kg/min)	1,103.1 (605.1–1,458.3)	1,069.2 (605.1–1,395.4)	1,092 (564.7–1,469.2)	1,323.3 (653.3–1,842.1)	0.233
At the time of starting hydrocortisone treatment
HR (beats/min)	110 (90–128)	113 (92–131)	108 (84–123)	99 (84–107)	0.090
MAP (mm Hg)	72 (66–81)	71 (64–80)	75 (70–82)	76 (68–82)	0.050
NEQ (µg/kg/min)	0.25 (0.12–0.49)	0.30 (0.15–0.51)	0.17 (0.15–0.42)	0.06 (0.05–0.11)^a)	< 0.001
MAP/NEQ index (mm Hg/µg/kg/min)	276.8 (150.9–562.2)	245.4 (131.3–481.9)	432.2 (214.3–517.3)	1318.5 (809.1–1925.5)^a),b)	< 0.001

Group	In-hospital mortality, No. (%)	OR (95% CI)		Adjusted P-value
Group	In-hospital mortality, No. (%)	Unadjusted	Adjusted^a)	Adjusted P-value
Unchanged	101 (64.7)	Reference	Reference	Reference
Gradually increased	7 (24.1)	0.17 (0.07–0.43)	0.15 (0.05–0.40)	<0.001
Rapidly increased	6 (33.3)	0.27 (0.10–0.76)	0.29 (0.09–0.92)	0.035

Table 1. Patient characteristics according to the MAP/NEQ index trajectories

Values are presented as median (interquartile range) or number (%).

a), b)

Indicates significant pairwise differences after correction as follows:

A significant difference compared with the unchanged group;

Indicates a significant difference compared with the gradually increased group;

P-values are derived from the overall comparison across the four trajectory groups, with statistical significance defined as P<0.05. Post hoc pairwise comparisons were performed using the Bonferroni correction.

Table 2. Hemodynamic variables at the time of shock diagnosis and of starting hydrocortisone according to the MAP/NEQ index trajectories

Values are presented as median (interquartile range).

MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose; HR: heart rate.

a), b)

Indicates significant pairwise differences after correction as follows:

A significant difference compared with the unchanged group;

A significant difference compared with the gradually increased group;

Table 3. ORs of in-hospital mortality according to the MAP/NEQ index trajectories

MAP: mean arterial pressure; NEQ: norepinephrine equivalent dose; OR: odds ratio.

Adjusted for age, nosocomial infection, intravenous fluid resuscitation, appropriate antibiotics, noncardiovascular Sequential Organ Failure Assessment score, and initial lactate level.